In vitro evaluation of drugs for interaction with transporters is essential during drug development. As polyspecific organic cation transporters (OCTs) are critical for pharmacokinetics of many cationic drugs, in vitro testing of human OCT1 and human OCT2 is recommended. In the currently applied tests it is determined whether uptake of one model cation in stably transfected epithelial cells is inhibited using a substrate concentration in the micromolar range. In this review experimental evidence for the existence of low-and high-affinity cation binding sites in OCTs that may interact with drugs is compiled. Most data were obtained from studies performed with rat Oct1. Whereas overlapping low-affinity cation binding sites are directly involved in transport, the high-affinity cation binding sites may induce allosteric inhibition of transport. Remarkably, high-affinity inhibition is only observed when uptake is measured using nanomolar substrate concentrations far below the respective K m values. Affinities of inhibitors are dependent on molecular structure and concentration of the employed substrate. Because the currently applied in vitro tests for identification of interaction of novel drugs with OCTs do not consider the influence of substrate structure and are not capable of identifying high-affinity inhibition, more sophisticated testing protocols are proposed.
Introduction
The polyspecific organic cation transporters OCT1 (SLC22A1), OCT2 (SLC22A2) and OCT3 (SLC22A3) are critically involved in absorption, disposition and excretion of many cationic drugs (Nies et al., 2010; Koepsell, 2013) . They also influence homeostasis of various endogenous cations and are involved in physiological processes. Rat OCT1 (rOct1) was cloned in 1994 (Gründemann et al., 1994) , rat OCT2 (rOct2) in 1996 (Okuda et al., 1996) and OCT3 from rat and human in 1998 (SLC22A3) (Gründe-mann et al., 1998; Kekuda et al., 1998) . After cloning, attempts were made to elucidate the transport function, physiological role and biomedical impact of the individual organic cation transporters (OCTs). In these studies that have been reviewed earlier (Dresser et al., 2001; Wright and Dantzler 2004; Koepsell et al., 2007; Nies et al., 2010; Koepsell, 2013) , substrate and inhibitor selectivities, tissue distributions, membrane locations and expression levels of the individual transporters were investigated. They provided a basic understanding regarding polyspecificity and electrogenicity for OCT1, OCT2 and OCT3, however, uncertainties concerning the physiological and biomedical roles of the individual human OCTs remained. The reason for the uncertainties is that detailed investigation of the transport mechanism has only been performed with rOct1 and rOct2 and that there are species differences between human and rodents concerning tissue distribution, expression level and selectivity Jonker et al., 2003) .
To identify new molecular entities (NMEs) that interact with human OCTs during drug development in vitro studies on overexpressed human transporters are required. As all efforts must be undertaken to avoid adverse drug effects of novel drugs, it should not be tolerated if more than 0.5% of interacting NMEs are not recognized and escape preclinical in vivo testing and clinical evaluation. Hence, the exclusion of NMEs for in vitro testing based on the available pharmacophore models for hOCT1 and hOCT2 indicated in Table 1 that have a predictive probability for interaction of NMEs between 69% and 82%, is not acceptable (Ahlin et al., 2008; Xu et al., 2013; Chen et al., 2017) . For the identification of NMEs that interact with OCT1 and OCT2 in vitro inhibition measurements have been proposed (Giacomini et al., 2010; ZamekGliszczynski et al., 2018) and in vitro evaluation strategies for the interaction of drugs with hOCT1 and hOCT2 have been recommended by the Food and Drug Administration and the European Medicines Agency.
The understanding of how polyspecific OCTs function is required to anticipate how drugs may interact with the OCTs and how they may change OCT-mediated cellular uptake or efflux of co-applied drugs and endogenous substrates. It is also essential for the design of in vitro assays that allow a reliable identification of NMEs that interact with OCTs and for a comprehensive characterization of drug-drug interactions at these transporters. Such understanding includes knowledge concerning the potential modes of operation, the underlying transport mechanisms, and the structural basis for polyspecific cation recognition. Although some basic functional studies have been performed with hOCT1 (Gorboulev et al., 1997; Zhang et al., 1997) , hOCT2 (Gorboulev et al., 1997; Busch et al., 1998) and hOCT3 (Gründemann et al., 1998) detailed functional studies are only available for rOct1 and rOct2. In rOct1 and rOct2 different potential transport modes have been investigated employing several experimental setups (Busch et al., 1996a,b; Nagel et al., 1997; Budiman et al., 2000; Volk et al., 2003; Keller et al., 2005 Keller et al., , 2008 Keller et al., , 2011 ) whereas a detailed investigation concerning the structural basis for polyspecificity was performed for rOct1 (Gorboulev et al., , 2018 Popp et al., 2005; Schmitt and Koepsell, 2005; Sturm et al., 2007; Schmitt et al., 2009; Volk et al., 2009; Egenberger et al., 2012) . In the studies on rOct1, effects of various mutations on apparent Michaelis-Menten contant (K m ) values and half maximal concentration for inhibition of transport (IC 50 ) were measured and interpreted with the help of homology models of threedimensional (3D) structures of the outward-open conformations of rOct1 and hOCT1. Measuring apparent K m and IC 50 values for rOct1 by different methods, we observed that large differing values were obtained when the overexpressed transporter was analyzed under different experimental conditions (Gorboulev et al., 2018) .
In the present review I shall depict the current knowledge concerning the transport mechanism of rOct1 and rOct2 that is supposed to also be valid for human OCTs. Second, I shall review mutagenesis studies in rOct1 which help to understand how structurally different substrates and inhibitors interact with OCT1. In a third section, I shall report the identification of inhibitory high-affinity cation binding sites in rOct1, hOCT1, hOCT2 and hOCT3. Fourth, evidence will be presented indicating that the experimental conditions employed for uptake measurement influence the determined K m and IC 50 values. Fifth, I shall review data in which the impact of the substrate concentration on the affinity of inhibitors is demonstrated. Thereafter, I shall discuss potential molecular reasons for the observed impact of experimental conditions on affinities. Finally, strategies for in vitro identification and characterization of drugs that interact with hOCT1, hOCT2 and hOCT3 will be proposed.
Transport modes and transport mechanism of rOct1 and rOct2
Transport by rOct1 and rOct2 has been investigated employing a large variety of methodological approaches. In oocytes of Xenopus laevis in which rOct1 or rOct2 were expressed, uptake and efflux of radioactively labeled substrates were measured, cation-induced short-circuit currents were analyzed and cation-induced capacitance Xu et al., 2013 In vitro testing was performed in adherent HEK293 cells expressing hOCT1 or hOCT2 using 4-(4-(dimethylamino)styryl)-N-methylpyridinium
changes were determined (Gründemann et al., 1994; Busch et al., 1996b Busch et al., , 1998 Nagel et al., 1997; Budiman et al., 2000; Arndt et al., 2001; Volk et al., 2003; Schmitt and Koepsell, 2005) . In oocytes expressing rOct2 parallel measurements of uptake of radioactively labeled substrates and the induced currents were performed (Schmitt et al., 2009) . Moreover, electrical measurements were performed in inside-out macropatches from oocytes expressing rOct2 (Budiman et al., 2000; Volk et al., 2003) . Furthermore, uptake of radioactively labeled cations was measured in proteoliposomes in which purified rOct1 or rOct2 had been reconstituted (Keller et al., 2005 (Keller et al., , 2008 . The data indicate that rOct1 and rOct2 are facilitative diffusion systems that can operate in several ways (Koepsell, 2011) . Less detailed functional characterizations of hOCT1 and hOCT2 ( Gorboulev et al., 1997; Zhang et al., 1997; Busch et al., 1998) suggest that the human and rat transporters have the same basic transport properties.
In the absence of cationic substrate on the transmembrane side the transporters can operate as electrogenic uniporters that may mediate cellular cation uptake or cation efflux (Figure 1 ). The driving force for these processes can be provided by the cation concentration gradients and/or by the membrane potential. Hence, in cells with normal inside-negative membrane potential transzero cation uptake is energetically preferred whereas trans-zero cation efflux can only occur in depolarized cells or in the presence of a large outwardly-directed cation gradient that overcomes the membrane potential. The re-orientations of the unloaded transporter may be the rate-limiting steps of cation uniport ( Figure 1A and B). Given that one cation is transported into the cell per cycle and the intracellular concentration of cationic substrate is high enough to saturate one inwardly oriented cation binding site, the transporter operates as an electroneutral cation exchanger ( Figure 1C ). When the extracellular and intracellular cationic substrate is identical, and the plasma membrane potential is zero, no net cation import or export takes place. Uptake of a given cation is stimulated when a different cationic substrate is present on the trans-side and the reorientation of the inward-open to the outward-open conformation of the loaded transporters is more rapid than the reorientation of the unloaded transporter (trans-stimulation). This was demonstrated for transport of 1-methyl-4-phenylpyridinium
showing that uptake of radioactively labeled MPP + into voltage-clamped proteoliposomes reconstituted with rOct1 was stimulated when the proteoliposomes had been loaded with choline, another substrate of rOct1 (Keller et al., 2005) .
Because OCT1, OCT2 and OCT3 are electrogenic transporters that employ the inside-negative membrane potential as the driving force they preferably mediate cellular uptake of organic cations. For example, OCT1 mediates cellular uptake of organic cations across the brush-border of the small intestine (Han et al., 2013) and cellular uptake across the sinusoidal membrane of hepatocytes (Nies et al., 2009; Koepsell, 2013) . OCT2 preferably mediates cellular uptake of organic cations across the basolateral membrane of renal proximal tubules (Koepsell, 2013) and into neurons (Busch et al., 1998) . OCT2 in the basolateral membrane of renal tubular cells may also operate as an electroneutrol cation exchanger when the intracellular and extracellular concentrations of cationic substrates are similar. In the presence of a sufficiently high outwardlydirected cation gradient OCTs may mediate cation efflux in the absence of extracellular cations as proposed for hOCT2-mediated efflux of acetylcholine in bronchial epithelial cells (Lips et al., 2005) . To date the in vivo relevance for OCT-mediated cation export out of cells has not been demonstrated.
Mutagenesis combined with 3D homology modeling indicated that rOct1 may occupy conformations with an outward-open substrate binding cleft and an inwardopen substrate binding cleft ). Inhibiting tetraethylammonium + (TEA + ) induced short-circuit inward currents by application of corticosterone from the extracellular or intracellular side showed that several amino acids that are located within inward parts of the modeled outward-open and inward-open clefts are accessible from extracellular and intracellular . This is consistent with an alternative access transporter model (Figure 2 ). Measuring the stoichiometries between rOct2 mediated translocation of positive charge and MPP + in oocytes clamped to zero mV, a charge/MPP + stoichiometry of 4 was determined, whereas the charge/ MPP + ratio approached unity at increasing inside negative membrane potentials (Schmitt et al., 2009) . The data indicate that at zero membrane potential three inorganic cations are translocated together with one MPP + molecule whereas at negative membrane potential one MPP + molecule is translocated without co-translocation or slippage of inorganic cations. The data imply the transient existence of a transporter conformation in which the substrate is occluded as depicted in Figure 2 . The size of the occlusion cavity appears to be different at different membrane potentials. The existence of a transient occluded state is also supported by the observation that organic cation transport by rOct1 was blocked when glycine in a glycineglycine motif in the middle of the 11th transmembrane α-helices (TMH) that allows bending of the α-helix, was mutated (Egenberger et al., 2012) . This indicates that bending of TMH 11 which is supposed to be involved in the formation of the occluded state, is required for transport. Note, that 3D homology models of outward-open conformations of rOct1 and hOCT1 Dakal et al., 2017) and of the inward-open conformations of rOct1 only contain unbended TMHs (Popp et al., 2005) , and that a direct transition of the modeled outward-open to the inward-open conformation without considerable slippage of small ions is difficult to imagine.
Molecular understanding of how substrates and inhibitors may interact with OCT1
Extensive mutagenesis was performed in rOct1. After expression of rOct1 wild-type and mutants in oocytes effects on apparent K m values of transported cations and on IC 50 values of inhibitors were determined Popp et al., 2005; Volk et al., 2009) . It was observed that mutations of amino acids located within the modeled outward-open binding cleft exhibited different effects on apparent K m values of several substrates and on IC 50 values of several inhibitors. These observations were interpreted to indicate that rOct1 contains a substrate binding region within the inner part of the outward-facing cleft which contains partially overlapping binding sites for different substrates and inhibitors. Because we used a 30 min-incubation time for the uptake measurements in oocytes during which the transport mode may have changed, the molecular interpretation was arguable. Hence, we investigated the effects of mutations in five positions within the modeled outward-facing cleft of rOct1 employing stably transfected human embryonic kidney (HEK) 293 cells and measuring initial uptake rates using incubation times of 1 to 10 s (Gorboulev et al., 2018) (Figure 3 Figure 3B ).
Recently we measured binding of radioactively labeled MPP + to cell-free expressed rOct1 and rOct1 mutants that were reconstituted into nanodiscs formed from 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and His-tagged membrane scaffold protein MSP1 (Roos et al., 2012 (Roos et al., , 2013  Figure 2: Three-state model of an alternating access organic cation transporter allowing the translocation of organic cations across the plasma membrane without slippage of small ions as was observed for rOct1 at negative membrane potential. Translocation of one organic cation per translocation cycle is depicted. Keller et al., unpublished data + and rOct1 cannot be transferred one to one to interaction of individual drugs with hOCT1, however, considering the large homology and similar functional properties of rOct1 and hOCT1, it is probable that some clinically relevant drugs interact in a similar way with hOCT1.
Identification of inhibitory highaffinity cation binding sites in OCTs
In an rOct1 variant in which ten cysteine residues were replaced by serine (Sturm et al., 2007) and Phe483 in TMH 11 close to the extracellular surface was exchanged by cysteine (rOct1-10ΔC(F483C)) and labeled with the fluorescent dye tetramethylrhodamine-6-maleimide (TMRM) ( Figure 4A ), voltage-clamp fluorometry measurements were performed (Gorbunov et al., 2008) . When the membrane potential was changed from +50 mV to −150 mV the fluorescence of TMRM was increased. The potentialdependent fluorescence changes were blunted in the presence of different concentrations of transported cations such as TEA + , choline + or MPP + ( Figure 4B) , and of the non-transported inhibitor TBuA + ( Figure 4C ) indicating movements of TMRM that are induced allosterically by cation binding. Importantly, not only low-affinity effects representing interaction with low-affinity sites but also high-affinity binding effects of TEA + , choline + uptake was measured. Thinking about the physiological and biomedical roles of high-affinity cation binding sites in OCTs we reasoned that binding of cationic inhibitors to high-affinity sites may only cause inhibition of transport when the transporters operate far below the apparent K m values of the respective cationic substrates. To evaluate the interaction of nucleoside reverse transcriptase inhibitors (NRTIs) which are used for the treatment of HIV-1 infection, with hOCT1, hOCT2 and hOCT3, we measured the inhibition of initial uptake rates of MPP + in stably transfected Chinese ovary cells by NRTIs including lamuvidine (3TC) and tenofovir disoproxil fumarate (TDF) (Minuesa et al., 2009 ). To enable the detection of inhibitory high-affinity sites, we used a low concentration of 12.5 nm MPP + for the uptake measurements. We observed that the NRTIs inhibited MPP + uptake by 40-70% with high-affinity whereas millimolar concentrations of NRTIs were required to inhibit the remaining 30-60% of MPP + uptake. For high-affinitiy inhibition IC 50 values between 5 pm and 0.9 nm were determined. For example, TDF inhibited uptake of 12.5 nm MPP + mediated by hOCT1, hOCT2 and hOCT3 with IC 50 values of 0.85 nm, 0.57 nm and 5 pm, respectively, whereas for the inhibition of MPP + uptake by 3TC IC 50 values of 12 pm (hOCT1), 8 pm (hOCT2) and 15 pm (hOCT3) were determined. The IC 50 for 3TC was increased 12-fold and 170-fold when 0.13 μm or 5 μm MPP + were used for uptake, respectively. Employing 1 μm MPP + for the uptake measurements and using an incubation time of 1 min, inhibition of hOCT1-mediated uptake by 10 μm TDF could not be detected (Minuesa et al., 2017; Shen et al., 2017) . 3TC is transported by hOCT1, hOCT2 and hOCT3 with apparent K m values between 1.3 and 2.1 mm (Minuesa et al., 2009 between 1.9 mm and 3.5 mm were resolved in addition to the high-affinity inhibitory sites. The data indicate the coexistence of the high-and low-affinity 3TC binding sites.
Performance of uptake measurements influences apparent K m and IC 50 values
Substantial differences in apparent K m and IC 50 values for expressed OCT1 and OCT2 transporters have been reported from different laboratories measuring tracer uptake in oocytes using incubation times of more than 10 min (Gorboulev et al., 1997 Zhang et al., 1997; Nies et al., 2010) , measuring initial tracer uptake rates in suspended HEK293 cells (Busch et al., 1996a; Egenberger et al., 2012) and measuring tracer uptake in HEK293 cells that were adherent to culture dishes using incubation times of several minutes (Nies et al., 2009; Tzvetkov et al., 2012; Matthaei et al., 2016; Chen et al., 2017) . To elucidate whether the different results are due to methodological differences, we performed tracer uptake measurements in oocytes in which rOct1 or rOct1 mutants were expressed by cRNA injection and in HEK293 cells that were stably transfected with rOct1 or rOct1 mutants (Gorboulev et al., 2018) . In oocytes, tracer uptake was measured after 30 min incubation whereas in HEK293 cells tracer uptake was either measured in cells adherent to culture dishes using 2 min-incubation or in cell suspensions using an incubation time of 1-10 s. We determined apparent K m values for uptake of TEA + or MPP + and IC 50 values for inhibition MPP + uptake by the non-transported inhibitor TBuA + . The apparent K m values for TEA + uptake measured in adherent HEK293 cells were more than 5 times higher compared to the values determined in suspended HEK293 cells and in oocytes whereas the apparent K m values for MPP + uptake measured in adherent HEK293 cells were more than 15 times higher compared to the values obtained under the two other experimental conditions ( Figure 5A ). To determine whether the effects of mutations on apparent K m values are detected equally using different methods, we also measured the apparent K m values for MPP + uptake in rOct1 mutants in which Tyr222 was replaced by phenylalanine or Asp475 by glutamate ( Figure 5B ). After replacement of Tyr222 an effect on the apparent K m value was only detected in oocytes whereas after replacement of Asp475 a significant effect was only observed in measurements performed with adherent HEK293 cells. Measuring IC 50 values for inhibition of the uptake of 0.1 μm MPP + by •p < 0.05 for difference to wild-type, *p < 0.05. The data are taken from Gorboulev et al. (2018) .
TBuA
+ largely different effects were observed under the three experimental conditions ( Figure 5C ). Significant effects of the Y222F exchange were observed in adherent and suspended HEK293 cells but not in oocytes. The effect observed in HEK293 cells was significantly larger when uptake was measured in adherent cells. After replacement of Asp475 by glutamate the IC 50 for TBuA + inhibition was decreased by 50%, 94% and 96% when the MPP + uptake was measured in suspended HEK293 cells, adherent HEK293 cells or oocytes, respectively.
Impact of the employed substrate and substrate concentration on affinities of inhibitors
It has been reported that different IC 50 values for inhibition of hOCT2-mediated uptake were obtained when different organic cations were employed for uptake measurements (Belzer et al., 2013; Thevenod et al., 2013; Yin et al., 2016) + uptake expressed in HEK293 cells (Zolk et al., 2009) . In these studies substrate concentrations in the range of the respective K m values were employed. For most inhibitors higher IC 50 values were obtained using MPP + as substrate compared to NBD-MTMA + . In Table 2 IC 50 values of three inhibitors are indicated which were obtained for inhibition of hOCT2 mediated uptake of MPP + , Asp + , metformin or atenolol expressed in HEK293 cells using substrate concentrations far below the K m values of the respective substrates (Thevenod et al., 2013; Yin et al., 2016) . Whereas the employed experimental conditions using MPP + or Asp + as substrates were similar they were virtually identical using metformin versus atenolol as substrates. For inhibition of MPP + uptake by cimetidine a 20-fold higher IC 50 value was obtained compared to inhibition of Asp + uptake whereas the IC 50 value determined for inhibition of MPP + uptake by corticosterone was 9-fold lower compared to the value obtained with Asp + . About 10-fold lower IC 50 values for inhibition by cimetidine and pyrimetamine were obtained using atenolol versus metformin as substrate. The data indicate that the substrate effect on inhibitor affinity is dependent on both, the employed substrate and inhibitor.
Considering the presence of allosteric high-affinity MPP + binding sites in OCT1 that may inhibit MPP + transport allosterically (Gorbunov et al., 2008; Minuesa et al., 2009 Minuesa et al., , 2017 , we investigated whether different IC 50 values were obtained for the inhibition of MPP + uptake by TBuA + when different MPP + concentrations far below the apparent K m value for MPP + were employed for uptake measurements (Gorboulev et al., 2018) . To determine whether the effects of mutations on IC 50 values may be influenced by the employed substrate concentration we performed the measurements with rOct1 wild-type and the rOct1 mutants Y222F and D475E (Figure 6 ) (Gorboulev et al. 2018) . In these measurements initial uptake rates of MPP + were measured in dissociated stably transfected HEK293 cells. As demonstrated for inhibition of hOCT1-mediated MPP + uptake by pentamidine and quinidine (Minuesa et al., 2017) , different IC 50 values for inhibition of rOct1-mediated MPP + uptake were observed when different MPP + concentrations were used for the uptake measurements. The IC 50 for TBuA + obtained with 12.5 nM MPP + was 2.6 and 4.4 times lower compared to the values obtained with 0.25 nm or 100 nm MPP + , respectively. Noteworthy, Figure 6 ). Using 0.25 nm MPP + for the uptake measurements, the IC 50 for TBuA was decreased 3.8-fold when Tyr222 was replaced by phenylalanine whereas this mutation had no significant effect on the IC 50 for TBuA + when the uptake measurements were performed with 12.5 nm or 100 nm MPP + . When Asp475 was replaced by glutamate no effect on the IC 50 value for TBuA + was detected when 0.25 nm or 12.5 nm MPP + was employed for the uptake measurements. In contrast the IC 50 for TBuA + was 12-fold decreased when the uptake measurements were performed with 100 nm MPP + .
Potential molecular reasons for the impact of employed substrates and substrate concentrations on IC 50 values
Functional characterization and mutagenesis of rOct1 revealed that the recognition of substrates and inhibitors and the translocation of organic cations by rOct1 are highly complex. This is due to the situation that rOct1 not only contains overlapping binding sites for different substrates which are directly involved in transport, but also highaffinity binding sites that may trigger allosteric effects on high-and low-affinity cation binding sites and/or on transport-related conformational chances. The complexity of ligand interaction with rOct1 may be further increased by the quaternary structure of rOct1 containing interacting monomers that may promote allosteric effects (Keller et al., 2011) . In addition, complexity of ligand interaction is increased by the possibility that one individual substrate may bind to two or more transport-related low-affinity binding sites in one rOct1 monomer as suggested by recent measurements performed with MPP + (Keller et al., unpublished data) . The observations that different IC 50 values for inhibitors were determined when different substrates were employed (see Table 2 ) can be explained by differential interactions at overlapping or separate transport-relevant cation binding sites that may occur in combination with differential allosteric interactions of high-affinity binding sites. How can it be explained that hOCT1-mediated highaffinity inhibition of MPP + uptake by lamuvidine and other NRTIs was only observed when a very low MPP + concentration was used for the uptake measurements (Minuesa et al., 2009 (Minuesa et al., , 2017 Figure 6 ). Considering the overlapping polyspecificity of OCT1-3 and some structural and functional differences between individual OCT subtypes and different species diverging scenarios how drugs may interact with OCTs are anticipated.
Strategies for in vitro identification drugs that interact with human OCTs
In vivo OCTs may operate in various different ways. This is dependent on extracellular and intracellular concentrations of exogeneous and endogeneous substrates, on concentrations of non-transported inhibitors, and on different regulatory states of the transporters . It is considered a futile approach trying to mimick the potential in vivo affinities for in vitro identification of all interacting NMEs by inhibition experiments. Hence, I recommend in vitro inhibition experiments in which a set of the most sensitive experimental conditions is employed that cover the range of in vivo concentrations. Considering the impact of the substrate on inhibitor affinity the inhibition studies should be performed using three substrates with diverse molecular structures. One clinically relevant drug should be included as also commended (U.S. Food and Drug Administration, 2017). The apparent K m values of these substrates should be in the micromolar range and highly sensitive uptake assays should be used to allow sensitive uptake measurements with nanomolar substrate concentrations that are required to detect high-affinity inhibition (Minuesa et al., 2009 (Minuesa et al., , 2017 . Because high-affinity inhibition of OCTs is only observed using substrate concentrations far below their respective K m values and the highest inhibitor affinity may be only observed within a certain range of substrate concentrations (see Figure 6 ) it is recommended to use substrate concentrations which are about 10, 100 or 1000 times below the respective apparent K m values. It is a challenge to establish highly sensitive assays for measurement of initial uptake of nanomolar substrate concentrations that are appropriate for highthroughput screening of NMEs. Probably radioactively labeled substrates with high specific radioactivity have to be employed. Realizing the time and effort to test every cationic or noncharged drug in development under various different conditions for interaction with the three human OCTs, it would be very helpful if a pharmacophore modeling procedure could be established in which less than 0.5% false negative NMEs are predicted so that in vitro testing could be limited to NMEs that are positive in silico. Considering the various possibilities of inhibitory interactions at OCTs several pharmocophore models based on interaction analyses performed under different conditions have to be established. For in silico prediction these pharmacophore models should be employed one after the other.
In vitro characterization of drug-drug interactions at OCTs
When the interaction of a novel drug with a human OCT has been identified it must be evaluated whether the compound is transported. Therefore uptake must be analyzed by using a substrate concentration that is in the lower range of the free drug concentration in the blood of patients because the sensitivity of uptake assays for hydrophobic compounds is negatively correlated with drug concentration due to the background of passive absorption that increases linearly with concentration. If transport is observed, it has to be determined in preclinical and clinical studies whether the OCT-mediated transport has biomedical relevance. For transported or non-transported inhibitors in vitro drug-drug interaction studies with clinical relevant drugs showing OCT dependent absorption, distribution and/or excretion should be performed. IC 50 values for inhibition of uptake of the clinical relevant drugs by the new compounds should be determined using drug concentration for uptake measurements that are within the range of unbound drug concentrations in the blood of patients.
Concluding remarks
The reviewed data indicate that the currently employed in vitro assays for identification of novel drugs that interact with hOCT1 and hOCT2 are insufficient as they do not allow the detection of inhibitory high-affinity interactions. Current knowledge on the structure-function relationship in rOct1 provides molecular explanations for the observed complex low-and high-affinity inhibitory interactions of drugs. A new more sophisticated strategy for in vitro testing including improvement of uptake assays must applied to decrease the occurrence of adverse drug effects due to inhibition of OCTs in patients.
